The expression of waf‐1, p53 and bcl‐2 in prostatic adenocarcinoma

• Published in: British Journal of Urology 1997-02, Vol.79 (2), p.190-195
• Main Authors: Byrne, R.L., Wilson Horne, C.H., Robinson, M.C., Autzen, P., Apakama, I., Bishop, R.I., Neal, D.E., Hamdy, F.C.
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - metabolism; Aged; Aged, 80 and over; apoptosis; bcl‐2; Biological and medical sciences; Cyclin-Dependent Kinase Inhibitor p21; Cyclins - metabolism; Disease Progression; Enzyme Inhibitors - metabolism; Follow-Up Studies; Humans; Immunohistochemistry; Male; Medical sciences; Middle Aged; Neoplasm Proteins - metabolism; Nephrology. Urinary tract diseases; p53; Prostate cancer; Prostatic Neoplasms - metabolism; Proto-Oncogene Proteins c-bcl-2 - metabolism; Tumor Suppressor Protein p53 - metabolism; Tumors of the urinary system; Urinary tract. Prostate gland; waf‐1
• ISSN: 0007-1331; 1464-410X
• DOI: 10.1046/j.1464-410X.1997.03399.x

Objective To determine the associations between the expression of waf‐1 (a cyclin‐dependent kinase inhibitor regulated by p53), p53, bcl‐2 and tumour progression in prostate cancer. Patients and methods Samples of prostatic tissue were obtained by biopsy or at prostatectomy from 40 men (mean age 73 years, range 55–88) with histologically confirmed prostate cancer, examined using immunohistochemical staining for the three gene products, and the expression related to the stage, grade, disease progression and survival of the patients. Results Fifteen of 18 patients whose tumours were positive for waf‐1, 10 of 12 positive for bcl‐2 and 17 of 19 positive for p53 had disease progression. Fifteen of 19 patients positive for p53 had poorly differentiated tumours compared with 11 of 21 negative for p53 (P